Bcal Diagnostics
ASX:BDXSydney, Australia· Est.
Australian biotech delivering AI‑enhanced blood tests for early breast, pancreatic, and ovarian cancer detection.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian biotech delivering AI‑enhanced blood tests for early breast, pancreatic, and ovarian cancer detection.
Oncology
Technology Platform
Liquid chromatography‑mass spectrometry lipidomics combined with AI‑driven epigenomic DNA methylation analysis for non‑invasive cancer detection.
Opportunities
Expanding the blood‑test portfolio to additional cancer types and scaling distribution nationally and internationally, leveraging AI‑driven epigenomics for broader early‑detection applications.
Risk Factors
Regulatory and reimbursement hurdles, competition from larger liquid‑biopsy firms, and the need for sustained clinician adoption.
Competitive Landscape
Competes with liquid‑biopsy players such as GRAIL, Guardant Health, and Exact Sciences; differentiates through lipidomics, focus on women’s health, and integration with existing imaging pathways.